IP Library › Patent Application 12714920
Patent Application
App. No. 12/714,920

STABLE GABAPENTIN COMPOSITIONS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/714,920
Abstract

Stable compositions containing gabapentin compositions, methods of preparing such compositions, and methods of using such compositions.

Claims (33)

1 - 18 . (canceled)

19 . A composition, comprising gabapentin and at least one salt of a nonacidic cation and an anion of a mineral acid, wherein said composition comprises more than 20 ppm of said anion of a mineral acid, based on the amount of the gabapentin, and wherein:

said composition comprises at most 0.5% by weight of gabapentin lactam;

said nonacidic cation is selected from the group consisting of alkali metals, alkaline earth metals, and mixtures thereof; and

said anion of a mineral acid is selected from the group consisting of fluoride, chloride, bromide, iodide, sulfate, phosphate, and mixtures thereof.

20 . The composition of claim 19 , which comprises more than 25 ppm of said anion of a mineral acid, based on the amount of the gabapentin.

21 . The composition of claim 19 , which comprises more than 30 ppm of said anion of a mineral acid, based on the amount of the gabapentin.

22 . The composition of claim 19 , which comprises more than 50 ppm of said anion of a mineral acid, based on the amount of the gabapentin.

23 . The composition of claim 19 , which comprises more than 75 ppm of said anion of a mineral acid, based on the amount of the gabapentin.

24 . The composition of claim 19 , which comprises more than 100 ppm of said anion of a mineral acid, based on the amount of the gabapentin.

25 . The composition of claim 19 , which comprises more than 250 ppm of said anion of a mineral acid, based on the amount of the gabapentin.

26 . The composition of claim 19 , which comprises more than 500 ppm of said anion of a mineral acid, based on the amount of the gabapentin.

27 . The composition of claim 19 , which comprises more than 1000 ppm of said anion of a mineral acid, based on the amount of the gabapentin.

28 . The composition of claim 19 , which comprises more than 2000 ppm of said anion of a mineral acid, based on the amount of the gabapentin.

29 . The composition of claim 19 , which further comprises at most 5 ppm of one or more addition salts of gabapentin and an acid.

30 . (canceled)

31 . The composition of claim 19 , wherein said nonacidic cation is selected from the group consisting of lithium, sodium, potassium, magnesium, calcium, and mixtures thereof.

32 - 33 . (canceled)

34 . The composition of claim 19 , wherein said anion of a mineral acid is selected from the group consisting of fluoride, chloride, bromide, iodide, sulfate, phosphate, and mixtures thereof.

35 . The composition of claim 19 , wherein said anion of a mineral acid is chloride.

36 . The composition of claim 19 , wherein the salt of a nonacidic cation and an anion of a mineral acid comprises sodium chloride.

37 . The composition of claim 19 , which is in dry unit dosage form.

38 - 55 . (canceled)

56 . A method of treating a cerebral disease, comprising administering an effective amount of the composition of claim 19 to a subject in need thereof.

57 . The method of claim 56 , wherein said cerebral disease is epilepsy, faintness attacks, hypokinesia, dizziness, or cranial trauma.

58 . A method of improving cerebral function, comprising administering an effective amount of the composition of claim 19 to a subject in need thereof.

59 . The method of claim 58 , wherein said subject is a geriatric patient.

60 . A method of treating a neurodegenerative disorder, perinatal, comprising administering an effective amount of the composition of claim 19 to a subject in need thereof.

61 . The method of claim 60 , wherein said neurodegenerative disorder is stroke, Alzheimer's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, or Parkinson's disease.

62 . A method of treating depression, comprising administering an effective amount of the composition of claim 19 to a subject in need thereof.

63 . A method of treating anxiety, comprising administering an effective amount of the composition of claim 19 to a subject in need thereof.

64 . A method of treating or preventing panic attacks, comprising administering an effective amount of the composition of claim 19 to a subject in need thereof.

65 - 73 . (canceled)